Page 1 of 5 Date: 18/05/2017

Name: CEFABACTIN 500 MG TABLETS Revision: 1



### **SAFETY DATA SHEET**

(REACH regulation no. 1907/2006 and 453/2010)

# SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

#### 1.1 Product Identifier

Product name: Cefabactin 500 mg tablets

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use: Cefalosporin antibiotic for veterinary use

1.3 Details of the supplier of the safety data sheet

Registered company name: Le Vet Beheer B.V.

Address: Wilgenweg 7, 3421 TV Oudewater, The Netherlands

Telephone: +31-(0)348-565858. Fax: +31-(0)348-565454

info@levetpharma.com www.levetpharma.com

1.4 Emergency telephone number:

+31-(0)6-10203326

### **SECTION 2: HAZARDS IDENTIFICATION**

## Classification of the Substance or Mixture

GHS - Classification

Respiratory sensitization, Category 1 Skin sensitization, Category 1

**EU Classification:** 

EU Indication of danger: Danger

### **Label Elements**

Signal Word: Warning

**Hazard Statements:** H317 – May cause allergic skin reaction.

H334 – May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Precautionary Statements:** P261 – Avoid breathing dust.

P272 – Contaminated work clothing should not be allowed out of the workplace.

P285 – In case of inadequate ventilation wear respiratory protection.

**Response Phrases:** P302+352 – IF ON SKIN: Wash with plenty of soap and water.

P304+340 – IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. P333+313: If skin irritation or rash occurs, seek medical

advice/attention.

P342+311 – If experiencing respiratory symptoms call a POISON CENTER or

doctor/physician.



## **SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS**

#### 3.1 Substances

No substances fulfill the criteria set forth in annex II section A of the REACH regulation (EC) no. 1907/2006

# 3.2 Mixtures

Date: 18/05/2017

Page 2 of 5

Name: CEFABACTIN 500 MG TABLETS Revision: 1

#### Composition:

Ingredient	CAS-no.	Quantity
Cefalexine monohydrate	23325-78-2	500 mg
Lactose monohydrate	10039-26-6	Classified
Potato starch	9005-25-8	Classified
Colloidal anhydrous silica	7631-86-9	Classified
Magnesium stearate	557-04-0	Classified
Yeast, deactivated	-	Classified
Chicken flavour	-	Classified

### **SECTION 4: FIRST AID MEASURES**

**Description of First Aid Measures** 

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical

attention immediately.

**Skin Contact:** Remove contaminated clothing. Flush area with large amounts of water. Use soap.

Seek medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with

water. Do not induce vomiting unless directed by medical personnel. Seek medical

attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most important Symptoms and Effects, Both Acute and Delayed

**Symptoms and Effects** 

of Exposure: For information on potential signs and symptoms of exposure, See section 2 –

Hazards Identification and/or Section 11 – Toxicological Information.

**Medical Conditions** 

Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

**SECTION 5: FIREFIGHTING MEASURES** 

**Extinguishing Media:** Use alcohol-resistant foam, carbon dioxide, water or dry chemical spray

Special hazards arising from the substance or mixture

**Hazardous Combustion** 

**Products:** Products of combustion are carbon oxides (CO, CO2), nitrogen oxides (NO, NO2...).

sulfur oxides (SO, SO2,...).

Fire/Explosion Hazards: Not applicable

Advice for firefighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

Page 3 of 5 Date: 18/05/2017

Name: CEFABACTIN 500 MG TABLETS Revision: 1

### **SECTION 6: ACCIDENTAL RELEASE MEASURES**

## **Personal Precautions, Protective Equipment and Emergency Procedures**

Personnel involved in clean-up should wear appropriate personal protective equipment (See section 8). Minimize exposure.

#### **Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

# Methods and Material for Containment and Cleaning up

Measures for Cleaning /

**Collecting:** Contain the source of spill if it is safe to do so. Clean spill area thoroughly.

**Additional Consideration** 

for Large Spills: None

#### **SECTION 7: HANDLING AND STORAGE**

# **Precautions for Safe Handling**

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

# Conditions for Safe Storage, including any Incompatibilities

**Storage Conditions:** Store as directed by product packaging

Specific end use(s)

No data available.

# **SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION**

### **Control Parameters**

Occupational

**Exposure Limits:** No data available.

**Exposure controls** 

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures.

General room ventilation is adequate, unless the process generates dust, mist or

fumes.

**Personal Protective** 

**Equipment:** Refer to applicable national standards and regulations in the selection and use of

personal protective equipment (PPE).

Hands: None

Eyes: None

Skin: None

Page 4 of 5 Date: 18/05/2017

Name: CEFABACTIN 500 MG TABLETS Revision: 1

#### **SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**

**Physical State:** Round and convex flavoured tablet with a cross-shaped break line on one side.

Odor: Odourless

**Colour:** Light brown with brown spots

Molecular formula: Mixture
Molecular weight: Mixture

**Solvent Solubility:** Not applicable Water Solubility: Not applicable pH: Not applicable **Melting/Freezing Point:** No data available Boiling Point (°C): No data available **Partition Coefficient:** No data available No data available **Evaporation Rate:** No data available Vapor Pressure: Vapor Density: No data available Viscosity: No data available

#### Flammability:

Autoignition Temperature (Solid):No data availableFlammability (Solids):No data availableFlash Point (Liquid):No data availableUpper Explosive Limits (Liquid):No data availableLower Explosive Limits (Liquid):No data available

# **SECTION 10: STABILITY AND REACTIVITY**

# Reactivity

No data available

# **Chemical stability**

Stable under normal conditions of use.

### Possibility of hazardous reactions

No data available

# **Conditions to avoid**

Fine particles (such as dust and mists) may fuel fires/explosions.

### **Incompatible materials**

As a precautionary measure, keep away from strong oxidizers.

# **Hazardous decomposition products**

No data available

# SECTION 11: TOXICOLOGICAL INFORMATION

## **Information on Toxicological Effects**

**General Information:** Toxicological properties of the formulation have not been investigated. The

information in this section describes the potential hazards of the individual ingredients and the formulation. Routes of exposure: ingestion, eye contact, skin

contact.

Page 5 of 5 Date: 18/05/2017

Name: CEFABACTIN 500 MG TABLETS Revision: 1

**Toxicological effects:** Oral LD<sub>50</sub> (monkey): >1 g/kg; Oral TDLo (human): 14 mg/kg;

**Chronic toxicological Effects:** Cephalexin - Investigated as a reproductive effector. Cephalexin RTECS Number:

XI0350000

#### **SECTION 12: ECOLOGICAL INFORMATION**

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment

should be avoided.

**Toxicity:** No data available.

Persistence and Degradability: No data available

**Bio-accumulative Potential:** No data available

Mobility in Soil: No data available

#### **SECTION 13: DISPOSAL CONSIDERATIONS**

Waste treatment methods: Dispose of waste in accordance with all applicable laws and regulations. Member

State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive

techniques for waste and wastewater.

# **SECTION 14: TRANSPORT INFORMATION**

The following refers to all modes of transportation, unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

#### **SECTION 15: REGULATORY INFORMATION**

Safety, health and environmental regulations/legislation specific for the substance or mixture

Particular provisions: Veterinary medicinal product, under the scope of 2001/82/EC as amended

Chemical safety assessment: No data available

# **SECTION 16: OTHER INFORMATION**

Data Sources: The data contained in this SDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.